- CGI is uniquely positioned to deliver comprehensive immune marker and genomic data in oncology for biopharma partners and clinical centers for both solid and blood cancers
- CGI is also actively involved in 3 academic collaborations discovering and validating responder and non-responder patient groups for immuno-oncology drugs in melanoma, lung cancer and lymphoma
RUTHERFORD, N.J. & LOS ANGELES, May 04, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX); (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics announced today that the company is actively testing and providing data for 12 Immuno-Oncology (IO) clinical trials and 3 academic collaborations. The trials focus on solid tumors including lung, ovarian, head and neck, breast, urothelial and blood cancers including lymphomas and multiple myeloma.
CGI’s Rutherford, N.J. and Los Angeles, CA sites are both actively involved in delivering comprehensive immune marker and genomic data to support patient sub-typing and monitoring that can aid in the identification of targeted therapies for cancer patients.
“We started 2016 by actively providing PDL1 and PD1 data for three clinical trials and we are now actively supporting 12 clinical trials that we expect to ramp throughout 2016 and into 2017,” said Panna Sharma, CEO and President of Cancer Genetics, Inc. “We invested into diversifying our capabilities and technologies so that we could provide data and technology for genome, transcriptome and immune markers for subtyping, monitoring and response characterization in an therapeutic era where IO trials are rapidly increasing and changing patient outcomes.”
Immuno-oncology drugs are currently among the most effective types of cancer treatments, demonstrating success rates of 20 to 30 percent in certain targeted patients. The field of immuno-oncology is a highly promising area of medicine with healthcare analysts projecting over $35 billion in annual worldwide sales for immuno-oncology drugs by 2024, according to market research firm IMS Health.
“At this moment in time, personalized medicine is experiencing one of its brightest moments,” said Panna Sharma, President and CEO of Cancer Genetics, Inc. “Progressive therapies that identify biomarkers and improve outcomes for patients while managing costs are fueling the cancer care sector and CGI is at the center of this movement.”
CGI is the partner of choice for pharmaceutical and biotech companies because it offers an entire portfolio of immuno-oncology tests and technologies to help these companies improve the effectiveness and efficiency of their clinical trials and monitor patient response. In addition to its immuno-oncology portfolio, CGI integrates its expertise in genomic and biomarker data for oncology, offering a comprehensive and fully integrated proposition for biotech and pharma companies that makes scientific and economic sense.
At CGI’s centers of excellence in New Jersey and California, the company continues developing new offerings and expanding its existing capabilities in immuno-oncology and immunotherapy as well as integrating these capabilities with the genomic and biomarker-based testing it has historically offered.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.